Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Tempest Therapeutics Inc (TPST)

Tempest Therapeutics Inc (TPST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules GlobeNewswire - Wed Nov 26, 3:05PM CST

BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class 1 targeted and immune-mediated...

TPST : 2.93 (+0.69%)
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules GlobeNewswire - Tue Nov 25, 7:00AM CST

BRISBANE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class 1 targeted and immune-mediated...

TPST : 2.93 (+0.69%)
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 GlobeNewswire - Wed Nov 19, 8:00AM CST

All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T program Acquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR ⍺ Antagonist, Phase 3-ready) and...

TPST : 2.93 (+0.69%)
Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire - Wed Nov 5, 7:30AM CST

BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class 1 targeted and immune-mediated...

TPST : 2.93 (+0.69%)
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update GlobeNewswire - Mon Aug 11, 3:12PM CDT

Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in China Granted orphan drug designation from the European Medicines Agency...

TPST : 2.93 (+0.69%)
Survival Data and Regulatory Greenlights Fuel Momentum in Immunotherapy Stocks BayStreet.ca - Tue Jul 29, 12:10PM CDT

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Cancer is no longer just a disease of aging populations. Researchers are sounding the alarm over rising...

PSTV : 0.5800 (-8.96%)
ONCY : 1.0100 (-2.88%)
AIM : 1.3400 (-2.90%)
INTS : 0.4199 (-4.46%)
TPST : 2.93 (+0.69%)
ONC.TO : 1.42 (+2.16%)
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China GlobeNewswire - Mon Jun 30, 7:00AM CDT

TPST : 2.93 (+0.69%)
After Major Oncology Conference, All Eyes Turn to Industry Innovation Newswire.ca - Thu Jun 12, 8:00AM CDT

/CNW/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and...

ONCY : 1.0100 (-2.88%)
CTXR : 1.0400 (-5.45%)
TPST : 2.93 (+0.69%)
CTOR : 1.1600 (+8.41%)
CAH : 198.44 (+0.28%)
ONC.TO : 1.42 (+2.16%)
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock GlobeNewswire - Wed Jun 11, 7:00AM CDT

TPST : 2.93 (+0.69%)
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC GlobeNewswire - Thu Jun 5, 7:00AM CDT

TPST : 2.93 (+0.69%)

Barchart Exclusives

Why Short–Term Bond ETFs Might Be the Best Income Investment for 2026 Barchart - Wed Dec 17, 6:30PM CST
Forget betting on a turnaround in dividend stocks. Try these two ETFs instead. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot